THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
COSMETIC & COSMECEUTICAL INGREDIENT PROFILE CODE: [COS-17] ID: TIP-MED-000621

Madecassoside & Centella Triterpenes (TECA)

Active Ingredient / Scientific Identity: INCI: Madecassoside • Class: Cosmetic Science & Dermopharmaceutics • Pentacyclic Triterpenoid Saponin Skin-Soothing & Barrier Active

⚖️ Compare 579 Drugs
THE INDIAN PHARMACIST — Educational Reference Sheet
Profile: Madecassoside & Centella Triterpenes (TECA) ([COS-17] | ID: TIP-MED-000621) • Last Reviewed: 2026-11-10
Source URL: https://theindianpharmacist.com/medicine/cos-17-madecassoside/
Generic / Entity NameMadecassoside & Centella Triterpenes (TECA) ([COS-17])
Verified Indian Brands / RefINCI Standard: Madecassoside (IS 4707 / Cosmetics Rules, 2020 Compliant)
Pharmacological ClassCosmetic Science & Dermopharmaceutics • Pentacyclic Triterpenoid Saponin Skin-Soothing & B
Available Dosage Forms0.1% to 1.0% in soothing gels, cica-creams, and post-peel recovery emulsions; pH 5.0–7.0
Regulatory ClassificationCosmetic soothing ingredient under Cosmetics Rules, 2020.
Key Warning & Review DateHigh tolerability; rare allergic contact dermatitis in individuals sensitised to Apiaceae plants.
Reviewed: 2026-11-10
Safety Matrix:⚖️ Regulatory Framework: Cosmetic soothing ingredient under Cosmetics Rules, ✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Madecassoside & Centella Triterpenes (TECA) (TIP-MED-000621, Reference Code [COS-17]) is classified under Cosmetics & Cosmeceutical Ingredients (Cosmetics Rules, 2020) as a Cosmetic Science & Dermopharmaceutics • Pentacyclic Triterpenoid Saponin Skin-Soothing & Barrier Active. Within the Indian regulatory and compendial framework, it is governed under Cosmetic soothing ingredient under Cosmetics Rules, 2020..

Verified Indian Market Examples / Compendial Status:
INCI Standard: Madecassoside (IS 4707 / Cosmetics Rules, 2020 Compliant)
Formulation & INCI Specification: 0.1% to 1.0% in soothing gels, cica-creams, and post-peel recovery emulsions; pH 5.0–7.0. Regulated under the Cosmetics Rules, 2020 and Bureau of Indian Standards (BIS IS 4707).
Dosage Forms & Available Strengths:
0.1% to 1.0% in soothing gels, cica-creams, and post-peel recovery emulsions; pH 5.0–7.0
Routes: Topical Epidermal / Scalp Application Only (External Cosmetic Use)

Dermopharmaceutics, INCI Formulation & Cosmetics Rules 2020 Compliance

INCI Nomenclature:
Madecassoside
Cosmetic Function:
Pentacyclic Triterpenoid Saponin Skin-Soothing & Barrier Active
Evidence-Backed Concentration & pH Window:
0.1% to 1.0% in soothing gels, cica-creams, and post-peel recovery emulsions; pH 5.0–7.0

Irritation, Sensitisation & Photoprotection Considerations: High tolerability; rare allergic contact dermatitis in individuals sensitised to Apiaceae plants.

Chemical Stability & Formulation Incompatibilities: Water-soluble glycoside (unlike aglycones asiatic acid and madecassic acid, which require glycol/alcohol cosolvents).

Statutory Cosmetic vs Drug Distinction (Cosmetics Rules, 2020 & BIS IS 4707): Cosmetic soothing ingredient under Cosmetics Rules, 2020.

3. Mechanism of Action & Pharmacodynamics

Inhibits NF-kappa-B-mediated pro-inflammatory cytokines (IL-1beta, IL-6, TNF-alpha) in keratinocytes, stimulates Aquaporin-3 (AQP3) hydration channels and Lori-crin/Filaggrin barrier proteins, and modulates fibroblast Type I/III collagen balance.

4. Therapeutic Indications & Evidence-Supported Uses

  • Cosmetic soothing of redness-prone, barrier-compromised, or post-sun-exposed skin ('Cica' formulations)

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Cosmetic Formulation Concentration & pH Window: 0.1% to 1.0% in soothing gels, cica-creams, and post-peel recovery emulsions; pH 5.0–7.0

Administration & Meal Timing: External topical use only (0.1% to 1.0% in soothing gels, cica-creams, and post-peel recovery emulsions; pH 5.0–7.0). Water-soluble glycoside (unlike aglycones asiatic acid and madecassic acid, which require glycol/alcohol cosolvents).

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Stratum corneum partitioning and epidermal retention governed by molecular weight (<500 Da rule), logP, and formulation pH; cosmetic ingredients are formulated for local epidermal/corneocyte conditioning without systemic pharmacological action.
Metabolism & Biotransformation:
Local epidermal enzymatic hydrolysis or oxidation where applicable (e.g., esterases for retinyl/tocopheryl esters).
Elimination & Renal Adjustment:
Not applicable (topical cosmetic ingredient with negligible systemic exposure when used on intact skin).
Hepatic Impairment Considerations:
Not applicable (topical external cosmetic use).

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Known allergic contact dermatitis or hypersensitivity to Madecassoside
  • Application to open wounds, abraded skin, or acute infectious dermatoses
  • High tolerability; rare allergic contact dermatitis in individuals sensitised to Apiaceae plants.

Key Clinical Precautions: High tolerability; rare allergic contact dermatitis in individuals sensitised to Apiaceae plants.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • High tolerability; rare allergic contact dermatitis in individuals sensitised to Apiaceae plants.
Serious / Dose-Limiting Adverse Effects:
  • High tolerability; rare allergic contact dermatitis in individuals sensitised to Apiaceae plants.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • Water-soluble glycoside (unlike aglycones asiatic acid and madecassic acid, which require glycol/alcohol cosolvents).

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Formulation Stability & Compatibility Check: Water-soluble glycoside (unlike aglycones asiatic acid and madecassic acid, which require glycol/alcohol cosolvents).

Pharmacist Patient Counselling Points:

  • Perform a 24–48 hour forearm patch test before introducing a new active cosmeceutical onto facial skin.
  • Apply broad-spectrum SPF 30+ PA+++ sunscreen every morning, especially when using AHAs, BHAs, retinol, or brightening actives.
  • Cosmetic products clean, condition, or protect superficial skin appearance; persistent acne, melasma, rosacea, or eczema requires medical dermatology evaluation.

Storage, Stability & Dispensing Safeguards: Water-soluble glycoside (unlike aglycones asiatic acid and madecassic acid, which require glycol/alcohol cosolvents).

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Cosmetics Rules, 2020 (CDSCO, Ministry of Health & Family Welfare, Govt. of India); Bureau of Indian Standards (BIS) IS 4707 (Part 1 & Part 2) Classification of Cosmetic Raw Materials and Adjuncts.

Official Verification Portals: CDSCO — Cosmetics Division & Cosmetics Rules, 2020 • Bureau of Indian Standards (BIS) — IS 4707 Cosmetic Standards

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.

← Back to All 644 Reference Profiles 📖 Explore 40 Knowledge Hub Articles → ✉️ Report Errata / Feedback
Educational Reference Notice: This printout from THE INDIAN PHARMACIST (https://theindianpharmacist.com/medicine/cos-17-madecassoside/, Last Reviewed: 2026-11-10) is an educational reference sheet for students and healthcare learners. It is NOT an official prescribing guideline or patient-specific treatment order.